- Home
- CIFR vs CRSP Comparison
CIFR vs CRSP Comparison
Compare CIFR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- CRSP
- Stock Information
- Founded
- CIFR 2021
- CRSP 2013
- Country
- CIFR United States
- CRSP Switzerland
- Employees
- CIFR N/A
- CRSP N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIFR Finance
- CRSP Health Care
- Exchange
- CIFR Nasdaq
- CRSP Nasdaq
- Market Cap
- CIFR 6.7B
- CRSP 5.6B
- IPO Year
- CIFR N/A
- CRSP 2016
- Fundamental
- Price
- CIFR $19.07
- CRSP $61.10
- Analyst Decision
- CIFR Strong Buy
- CRSP Buy
- Analyst Count
- CIFR 10
- CRSP 18
- Target Price
- CIFR $16.83
- CRSP $73.47
- AVG Volume (30 Days)
- CIFR 51.4M
- CRSP 2.7M
- Earning Date
- CIFR 11-03-2025
- CRSP 11-04-2025
- Dividend Yield
- CIFR N/A
- CRSP N/A
- EPS Growth
- CIFR N/A
- CRSP N/A
- EPS
- CIFR N/A
- CRSP N/A
- Revenue
- CIFR $158,849,000.00
- CRSP $38,050,000.00
- Revenue This Year
- CIFR $81.55
- CRSP N/A
- Revenue Next Year
- CIFR $73.16
- CRSP $391.94
- P/E Ratio
- CIFR N/A
- CRSP N/A
- Revenue Growth
- CIFR 0.11
- CRSP N/A
- 52 Week Low
- CIFR $1.86
- CRSP $30.04
- 52 Week High
- CIFR $22.00
- CRSP $78.48
- Technical
- Relative Strength Index (RSI)
- CIFR 57.11
- CRSP 42.00
- Support Level
- CIFR $15.04
- CRSP $64.80
- Resistance Level
- CIFR $21.90
- CRSP $68.71
- Average True Range (ATR)
- CIFR 2.16
- CRSP 3.64
- MACD
- CIFR -0.24
- CRSP -1.46
- Stochastic Oscillator
- CIFR 54.45
- CRSP 7.35
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.